• SIGA Technologies, Inc. reported past fourth-quarter 2025 results with revenue of US$3.8 million and a net loss of US$5.4 million, while full-year 2025 revenue reached US$94.57 million with net income of US$23.28 million.
• At the same time, confirmation of a more severe mpox case in New York City has renewed attention on SIGA’s smallpox-related antiviral portfolio despite weaker quarterly earnings.
• Next, we’ll examine how the severe mpox case and SIGA’s focus on smallpox-related antivirals shape the company’s investment narrative.

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is SIGA Technologies' Investment Narrative?

To own SIGA today, you need to believe its niche in smallpox and orthopox antivirals can withstand lumpy government stockpiling and mixed clinical headlines. The latest quarter underscored that lumpiness: Q4 2025 revenue fell to US$3.8 million with a net loss of US$5.4 million, even though full-year numbers stayed profitable at US$94.57 million in revenue and US$23.28 million in net income. The confirmed severe mpox case in New York City may rekindle interest in TPOXX and related products, but it does not instantly change procurement cycles or the NIH trial setback that questioned tecovirimat’s benefit in mpox. Near term, the real swing factors are fresh contract wins or renewals, regulatory outcomes for broader indications, and whether recent share price pressure reflects transient concern or something more fundamental.

However, there is one area of contract risk that current shareholders really need to understand. Despite retreating, SIGA Technologies' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Thirteen fair value estimates from the Simply Wall St Community span roughly US$5.50 to above US$37 per share, underscoring how far apart views can be. When you set that against SIGA’s sharp quarterly earnings drop and dependence on sizeable, irregular government orders, it is worth weighing how different scenarios for future stockpiles could affect both sentiment and business momentum before drawing your own conclusion.

Explore 13 other fair value estimates on SIGA Technologies - why the stock might be worth just $5.50!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your SIGA Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free SIGA Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SIGA Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.